its CRP!!!
Cryptome to Apply its Drug Discovery Technology to
Neuroinflammatory Diseases
Sydney—16 December 2004: Cryptome Pharmaceuticals Ltd (ASX:CRP) announced today that
it is initiating a program to apply its proprietary CryptomicsTM drug discovery platform to the field of
neuroinflammatory diseases. The company has engaged Professor Claude Bernard, a world
authority on multiple sclerosis and other neuroinflammatory conditions, to lead the program.
The CryptomicsTM drug discovery platform is a systematic approach to the identification of protein
fragments with previously undiscovered therapeutic activities. This approach has already yielded a
novel drug candidate in the cardiovascular field (CR001) and hits are rapidly emerging for cancer.
The world market for drugs to treat neuroinflammatory diseases such as multiple sclerosis, stroke
and Alzheimer’s is currently about US$5 billion. With the ageing population, this market is
projected to double within five years. In this therapeutic area, many of the approved and emerging
drugs are proteins.
Cryptome’s Acting CEO, Professor Mathew Vadas said, “The strong market demand for protein
molecules for patients with neuroinflammatory disease represents a natural opportunity for
Cryptome. Our platform can rapidly produce drug candidates with improved efficacy and fewer side
effects.”
Professor Claude Bernard is the Foundation Director of the Neuroimmunology Laboratory and
Professor of Neuroimmunology in the Department of Biochemistry at La Trobe University. He has
made major contributions to the understanding of multiple sclerosis and autoimmunity; and has
published over 180 scientific papers, many in prestigious scientific journals such as Nature,
Science, Proceeding of the National Academy of Sciences, & the Journal of Experimental
Medicine.
Cryptome Chairman Graham Kelly said, “We are delighted to have someone of Professor
Bernard’s standing to join the Cryptome team. His consultant role in the program is consistent with
the company strategy of attracting the best specialist scientists to direct and oversee research
activities within the company in their respective fields of expertise. “
Professor Bernard has commenced discussions with potential collaborative partners to work with
Cryptome to drive the neuroinflammatory program forward. The partners will allow faster
development of libraries for screening on the CryptomicsTM platform and animal models for testing
of drug candidates to emerge from the screening process.
About Cryptome Pharmaceuticals
Cryptome Pharmaceuticals Ltd is a globally-linked, Melbourne-based biotechnology company
created to discover and develop effective and safe protein-derived medicines targeting cancer and
cardiovascular disease, using a proprietary proteomics-based technology platform. Cryptome
exploits evolution for accelerated drug discovery.
- Forums
- ASX - General
- this is not cr@p!
this is not cr@p!
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)